Tseng Fang-Wen, Vachiramon Vasanop, Gold Michael H, Pavicic Tatjana, Tay Clifton M, Toh Gerard W, Tan Diana M K, Park Je-Young
Everbeaute Medical Aesthetics, Taipei, Taiwan.
Division of Dermatology, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
J Cosmet Dermatol. 2025 Feb;24(2):e16686. doi: 10.1111/jocd.16686. Epub 2024 Dec 8.
Immunoresistance to botulinum neurotoxin A (BoNT-A) due to neutralizing antibodies (NAbs) can lead to partial or complete secondary nonresponse (SNR), potentially limiting individuals' aesthetic and/or medical therapeutic options in the short and/or long term. Understanding factors directly or indirectly influencing BoNT-A immunoresistance risk is crucial.
This analysis explored patterns of latent risk factors (biological and behavioral) that may influence the risk of developing BoNT-A immunoresistance among experienced aesthetic BoNT-A recipients.
Latent class analysis (LCA) was applied to survey data from 363 experienced BoNT-A recipients from six Asia-Pacific countries to identify distinct subgroups based on their patterns of risk factor or risk proxy variables. The five risk proxy variables used for modeling capture information on BoNT-A treatments (treatment indications/locations as proxies for dose), symptoms of declining efficacy, number of aesthetic treatments over the past 3 years, and clinic and BoNT-A formulation switching behaviors. These represent established risk factors and treatment-seeking behaviors suggested to influence immunoresistance risk.
LCA identified 3 distinct profiles of individuals, which we described based on the observed patterns of risk proxies as: "lower-risk" (55%), "moderate-risk" (39%), and "higher-risk" (6%). Individuals in the "higher-risk" profile reported higher BoNT-A exposure, more symptoms of declining efficacy, and distinct patterns of knowledge and attitudes toward BoNT-A immunoresistance that could account for their treatment-seeking behaviors.
This study suggests that individual behaviors (the "human factor") have a notable influence on BoNT-A immunoresistance risk. Gaining deeper insights into these factors could support more targeted and effective interventions to mitigate risk.
由中和抗体(NAbs)导致的对A型肉毒杆菌神经毒素(BoNT-A)的免疫抵抗可引起部分或完全的继发性无反应(SNR),这可能在短期和/或长期内限制个体的美容和/或医学治疗选择。了解直接或间接影响BoNT-A免疫抵抗风险的因素至关重要。
本分析探讨了潜在风险因素(生物学和行为学)的模式,这些因素可能影响有经验的美容BoNT-A接受者发生BoNT-A免疫抵抗的风险。
将潜在类别分析(LCA)应用于来自亚太地区六个国家的363名有经验的BoNT-A接受者的调查数据,以根据他们的风险因素或风险替代变量模式确定不同的亚组。用于建模的五个风险替代变量捕获有关BoNT-A治疗的信息(治疗指征/部位作为剂量的替代指标)、疗效下降的症状、过去3年的美容治疗次数以及诊所和BoNT-A制剂转换行为。这些代表了已确定的风险因素和建议的影响免疫抵抗风险的就医行为。
LCA确定了3种不同的个体特征,我们根据观察到的风险替代指标模式将其描述为:“低风险”(55%)、“中度风险”(39%)和“高风险”(6%)。“高风险”特征的个体报告了更高的BoNT-A暴露量、更多疗效下降的症状以及对BoNT-A免疫抵抗的独特知识和态度模式,这些可以解释他们的就医行为。
本研究表明个体行为(“人为因素”)对BoNT-A免疫抵抗风险有显著影响。更深入地了解这些因素有助于采取更有针对性和有效的干预措施来降低风险。